118 related articles for article (PubMed ID: 35259554)
21. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
Kwon MJ; Kang SY; Cho H; Lee JI; Kim ST; Suh YL
Brain Pathol; 2020 Mar; 30(2):235-245. PubMed ID: 31435963
[TBL] [Abstract][Full Text] [Related]
22. Comparative genomic hybridization reveals recurrent enhancements on chromosome 20 and in one case combined amplification sites on 15q24q26 and 20p11p12 in glioblastomas.
Brunner C; Jung V; Henn W; Zang KD; Urbschat S
Cancer Genet Cytogenet; 2000 Sep; 121(2):124-7. PubMed ID: 11063794
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
24. Microarray-based comparative genomic hybridization (array-CGH) as a useful tool for identifying genes involved in Glioblastoma (GB).
Ruano Y; Mollejo M; de Lope AR; Hernández-Moneo JL; Martínez P; Meléndez B
Methods Mol Biol; 2010; 653():35-45. PubMed ID: 20721736
[TBL] [Abstract][Full Text] [Related]
25. Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
Dono A; Amsbaugh M; Martir M; Smilie RH; Riascos RF; Zhu JJ; Hsu S; Kim DH; Tandon N; Ballester LY; Blanco AI; Esquenazi Y
J Neurooncol; 2021 Mar; 152(1):153-162. PubMed ID: 33492602
[TBL] [Abstract][Full Text] [Related]
26. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
[TBL] [Abstract][Full Text] [Related]
27. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Kim N; Kim SH; Kang SG; Moon JH; Cho J; Suh CO; In Yoon H; Chang JH
Radiat Oncol; 2020 Jul; 15(1):184. PubMed ID: 32736562
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
29. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
30. Assessment of alterations in gene expression in recurrent malignant glioma after radiotherapy using complementary deoxyribonucleic acid microarrays.
Joki T; Carroll RS; Dunn IF; Zhang J; Abe T; Black PM
Neurosurgery; 2001 Jan; 48(1):195-201; discussion 201-2. PubMed ID: 11152346
[TBL] [Abstract][Full Text] [Related]
31. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
32. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines.
Roversi G; Pfundt R; Moroni RF; Magnani I; van Reijmersdal S; Pollo B; Straatman H; Larizza L; Schoenmakers EF
Oncogene; 2006 Mar; 25(10):1571-83. PubMed ID: 16247447
[TBL] [Abstract][Full Text] [Related]
34. Glioblastomas harboring gene fusions detected by next-generation sequencing.
Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
36. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
37. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.
Grana C; Chinol M; Robertson C; Mazzetta C; Bartolomei M; De Cicco C; Fiorenza M; Gatti M; Caliceti P; Paganelli G
Br J Cancer; 2002 Jan; 86(2):207-12. PubMed ID: 11870507
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
39. Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses.
Magnani I; Moroni RF; Roversi G; Beghini A; Pfundt R; Schoenmakers EF; Larizza L
Cancer Genet Cytogenet; 2005 Sep; 161(2):140-5. PubMed ID: 16102584
[TBL] [Abstract][Full Text] [Related]
40. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization.
Weber RG; Sabel M; Reifenberger J; Sommer C; Oberstrass J; Reifenberger G; Kiessling M; Cremer T
Oncogene; 1996 Sep; 13(5):983-94. PubMed ID: 8806688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
